Cancer Fatigue: Review Integrates 10 Years of Evidence on Acupuncture and Moxibustion

Cancer-related fatigue (CRF) is the most prevalent and debilitating symptom among cancer patients — affecting between 60% and 90% of individuals on active treatment and persisting in up to 40% of long-term survivors. Unlike everyday fatigue, CRF is disproportionate to activity level, is not completely relieved by rest, and profoundly compromises quality of life, function, and the capacity for adherence to oncologic treatment. Despite this prevalence, no drug has demonstrated robust and consistent efficacy for CRF — making non-pharmacologic interventions particularly relevant.

A systematic review published in Supportive Care in Cancer, led by researchers from Malaysia, synthesizes a decade of evidence (2015–2025) on the use of acupuncture and moxibustion for cancer-related fatigue, with the distinction of being the first to integrate studies published in English and Chinese — substantially expanding the corpus of available data.

Why Integrating Chinese-Language Evidence Matters

A historical limitation of acupuncture reviews published in international journals is the systematic exclusion of clinical trials conducted and published in Mandarin. These studies constitute a significant part of worldwide scientific output on acupuncture and moxibustion — particularly in oncologic contexts, where decades of accumulated clinical experience exist. By including Chinese databases (CNKI, WanFang, VIP, CBM) along with international databases (PubMed, Cochrane, Web of Science, Embase), this review broadens the denominator of evidence and reduces the geographic publication bias that distorts exclusively Anglophone reviews.

The authors applied standardized inclusion criteria and uniform risk-of-bias assessment to all studies, regardless of publication language — ensuring methodologic comparability across evidence from both scientific traditions.

Interventions and Protocols Evaluated

The 13 RCTs evaluated different modalities of acupuncture and moxibustion in comparison with standard care alone, active controls, or pharmacologic treatments for fatigue. The protocols varied in duration and intensity, reflecting the diversity of approaches in clinical practice: short-term treatments (3 weeks or less), protocols synchronized with chemotherapy cycles, and prolonged treatments of up to 6 months. Needle retention time varied from 10 to 30 minutes across studies.

Moxibustion combined with standard oncologic care demonstrated superiority over standard care alone for severe fatigue — a relevant finding because it suggests that moxibustion may offer additional benefits to acupuncture for patients with more intense fatigue, possibly through its complementary thermal and immunologic effects.

Most Used Acupoints in the Studies

Analysis of the protocols revealed three acupoints selected most frequently in the 13 RCTs, all with neurophysiologic rationale relevant to fatigue modulation: Zusanli (ST-36), Qihai (CV-6), and Guanyuan (CV-4). The point Sanyinjiao (SP-6) also appeared with significant frequency. This convergence among independent studies — conducted by different research groups in different countries — suggests a clinical consensus on the most effective points for this indication.

Assessment Scales and Instruments Used

The studies used four validated instruments for fatigue assessment, ensuring standardization and comparability of outcomes: the Cancer Fatigue Scale (CFS), the Brief Fatigue Inventory (BFI), the Piper Fatigue Scale (PFS), and the Functional Assessment of Cancer Therapy – Fatigue (FACT-F). All instruments demonstrated consistent improvements in the intervention groups — agreement across different scales that reinforces the robustness of the findings.

Safety Profile

All 13 studies included in the review reported high safety profiles for acupuncture and moxibustion, with no serious adverse events documented. This information is particularly relevant in the oncologic context, where patients frequently present thrombocytopenia (reduction of platelets), neutropenia (reduction of neutrophils), and other hematologic side effects of chemotherapy that could theoretically increase risks of invasive procedures. The low rate of reported adverse events across 919 patients is favorable, but systematic safety monitoring in oncology requires attention to thrombocytopenia, neutropenia, and lymphedema áreas — context-specific precautions.

Limitations and Future Perspectives

Despite the consistency of the results, the authors recognize important limitations: relatively small sample sizes in individual studies, methodologic heterogeneity across protocols (variations in duration, frequency, and selection of acupoints), and variability in the outcome scales used — which made formal quantitative meta-analyses difficult. Standardization of acupoint protocols and assessment scales in future studies is identified as a fundamental step to enable more robust quantitative syntheses.

Even só, the consistency of favorable results across 13 independent trials, conducted by different research groups in distinct clinical contexts, and measured by four different validated scales, substantially strengthens the clinical plausibility of the intervention and justifies its consideration in the multidisciplinary management of cancer-related fatigue.